See the DrugPatentWatch profile for teflaro

What is Teflaro? And When Does the AbbVie Patent End?

Teflaro, also known as ceftobiprole, is a cephalosporin antibiotic used to treat bacterial infections. It is marketed by AbbVie, a global biopharmaceutical company. In this article, we will explore the patent status of Teflaro and when the AbbVie patent is expected to end.

What is Teflaro Used For?

Teflaro is a broad-spectrum antibiotic used to treat a range of bacterial infections, including community-acquired pneumonia, skin and skin structure infections, and complicated urinary tract infections. It is effective against a variety of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens.

AbbVie Patent for Teflaro

AbbVie holds the patent for Teflaro, which was first approved by the US Food and Drug Administration (FDA) in 2009. The patent was initially set to expire in 2026, but AbbVie has filed for extensions and has been granted several patent term extensions.

Patent Expiration Date

According to DrugPatentWatch.com, the patent for Teflaro is expected to expire on September 27, 2031. This means that AbbVie will no longer have exclusive rights to the drug, and other companies will be able to manufacture and market generic versions of Teflaro.

Why is Patent Expiration Important?

The expiration of a patent can have significant implications for the pharmaceutical industry. When a patent expires, generic versions of the drug can be manufactured and sold, which can lead to increased competition and lower prices for consumers. This can also lead to increased market share for generic manufacturers and potentially reduced revenue for the original patent holder.

Impact on Patients

The expiration of the Teflaro patent could have a significant impact on patients who rely on the drug for treatment. Generic versions of the drug may be less expensive and more accessible, which could improve treatment options for patients. However, the quality and efficacy of generic versions of the drug may vary, and patients should consult with their healthcare provider before switching to a generic version.

Conclusion

In conclusion, Teflaro is a broad-spectrum antibiotic used to treat a range of bacterial infections. The patent for Teflaro is held by AbbVie and is expected to expire on September 27, 2031. The expiration of the patent could lead to increased competition and lower prices for consumers, but it also raises concerns about the quality and efficacy of generic versions of the drug.

Frequently Asked Questions

Q: What is Teflaro used for?
A: Teflaro is used to treat bacterial infections, including community-acquired pneumonia, skin and skin structure infections, and complicated urinary tract infections.

Q: Who holds the patent for Teflaro?
A: AbbVie holds the patent for Teflaro.

Q: When does the patent for Teflaro expire?
A: The patent for Teflaro is expected to expire on September 27, 2031.

Q: What are the implications of patent expiration for patients?
A: The expiration of the patent could lead to increased competition and lower prices for consumers, but it also raises concerns about the quality and efficacy of generic versions of the drug.

Q: What should patients do if they are currently taking Teflaro?
A: Patients who are currently taking Teflaro should consult with their healthcare provider before switching to a generic version of the drug.

Sources:

1. DrugPatentWatch.com. (n.d.). Teflaro (Ceftobiprole). Retrieved from <https://www.drugpatentwatch.com/drug/teflaro-ceftobiprole>
2. AbbVie. (n.d.). Teflaro. Retrieved from <https://www.abbvie.com/our-science/teflaro.html>

Highlight:

"The expiration of a patent can have significant implications for the pharmaceutical industry, including increased competition and lower prices for consumers." - DrugPatentWatch.com